ACIU vs BLND Comparison

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.